Responding to the global challenges imposed by major depressive disorder requires meeting some of the unmet needs in the treatment of depression, as outlined on the slide.
References:
1.Kennedy SH, Lam RW, McIntyre RS, et al.; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry 2016; 61 (9): 540–460.
2.National Institute for Health and Care Excellence. Depression in adults: treatment and management. Guideline NG222, 2022.
3.Patel V, Araya R, Chatterjee S, et al. Treatment and prevention of mental disorders in low-income and middle-income countries. Lancet 2007; 370 (9591): 991–1005.
4.World Health Organization. Comprehensive mental health action plan 2013–2030. World Health Organization, 2021.
5.Oliveira-Maia AJ, Bobrowska A, Constant E, et al. Treatment-resistant depression in real-world clinical practice: A systematic literature review of data from 2012 to 2022. Adv Ther 2024; 41 (1): 34–64.
6.Patel V, Chisholm D, Parikh R, et al.; DCP MNS Author Group. Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. Lancet 2016; 387 (10028): 1672–1685.
